213 related articles for article (PubMed ID: 20019585)
1. Association of statins and diabetes mellitus.
Hagedorn J; Arora R
Am J Ther; 2010; 17(2):e52-5. PubMed ID: 20019585
[TBL] [Abstract][Full Text] [Related]
2. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
3. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events.
Michelena HI; Osorio LA; Citkowitz E
Int J Cardiol; 2005 May; 101(1):111-4. PubMed ID: 15860392
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
6. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
[TBL] [Abstract][Full Text] [Related]
7. (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
Noriega V; Pennanen C; Sánchez MP; Chiong M; Llancaqueo M; Lavandero S; Prieto JC
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):211-5. PubMed ID: 19067673
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
9. Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience.
Tan CE; Loh LM; Tai ES
Singapore Med J; 2003 Dec; 44(12):635-8. PubMed ID: 14770258
[TBL] [Abstract][Full Text] [Related]
10. The effect of pravastatin and atorvastatin on coenzyme Q10.
Bleske BE; Willis RA; Anthony M; Casselberry N; Datwani M; Uhley VE; Secontine SG; Shea MJ
Am Heart J; 2001 Aug; 142(2):E2. PubMed ID: 11479481
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374
[TBL] [Abstract][Full Text] [Related]
14. Keeping our eyes on the prize: low density lipoprotein cholesterol.
de Lemos JA; Khera A
Am J Cardiol; 2009 Dec; 104(12):1697-8. PubMed ID: 19962478
[No Abstract] [Full Text] [Related]
15. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
16. Achieving cholesterol goals. Current and future drug therapies.
Jones PH
Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
19. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Goumas GS
Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
[TBL] [Abstract][Full Text] [Related]
20. Diabetes and metabolic syndrome (MS).
Bellomo A; Mancinella M; Troisi G; Ettorre E; Marigliano V
Arch Gerontol Geriatr; 2007; 44 Suppl 1():61-7. PubMed ID: 17317435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
